Characteristics and outcomes of methicillin-resistant staphylococcus aureus bloodstream infections in patients with cancer treated with vancomycin: 9-Year experience at a comprehensive cancer center

Oncologist

Volumn 17, Issue 10, 2012, Pages 1329-1336

  Mahajan, Sminil N ^a   Shah, Jharna N ^a   Hachem, Ray ^a   Tverdek, Frank ^a   Adachi, Javier A ^a   Mulanovich, Victor ^a   Rolston, Kenneth V ^a   Raad, Issam I ^a   Chemaly, Roy F ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bacteremia; Bloodstream infections; Methicillin resistant Staphylococcus aureus; Vancomycin

Indexed keywords

DAPTOMYCIN; LINEZOLID; STEROID; TIGECYCLINE; VANCOMYCIN;

ADOLESCENT; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ARTICLE; ARTIFICIAL VENTILATION; BLOODSTREAM INFECTION; CATHETERIZATION; CHILD; DEATH; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HEMATOLOGIC MALIGNANCY; HOSPITALIZATION; HUMAN; INFANT; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MORBIDITY; MORTALITY; NEOPLASM; NEPHROTOXICITY; NEUTROPENIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RASH; RECURRENT DISEASE; RETROSPECTIVE STUDY; RISK FACTOR; SCHOOL CHILD; SECONDARY INFECTION; SEPSIS; SOLID TUMOR; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; BACTEREMIA; FEMALE; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 84868138512     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0029     Document Type: Article

References (38)

1. Steinberg JP, Clark CC, Hackman BO. Nosocomial and community-acquired Staphylococcus aureus bacteremias from 1980 to 1993: Impact of intravascular devices and methicillin resistance. Clin Infect Dis 1996;23:255-259.
2. Soriano A, Martinez JA, Mensa J et al. Pathogenic significance of methicillin resistance for patients with Staphylococcus aureus bacteremia. Clin Infect Dis 2000;30:368-373.
3. National Nosocomial Infections Surveillance (NNIS) report, data summary from October 1986-April 1996, issued May 1996. A report from the National Nosocomial Infections Surveillance (NNIS) system. Am J Infect Control 1996;24:380-388.
4. Fowler VG Jr., Sanders LL, Sexton DJ et al. Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: Experience with 244 patients. Clin Infect Dis 1998;27:478-486.
5. Mylotte JM, McDermott C, Spooner JA. Prospective study of 114 consecutive episodes of Staphylococcus aureus bacteremia. Rev Infect Dis 1987;9:891-907.
6. Jensen AG, Wachmann CH, Espersen F et al. Treatment and outcome of Staphylococcus aureus bacteremia: A prospective study of 278 cases. Arch Intern Med 2002;162:25-32.
7. Falcone M, Carfagna P, Cassone M et al. Staphylococcus aureus sepsis in hospitalized non neutropenic patients: Retrospective clinical and microbiological analysis. Ann Ital Med Int 2002;17:166-172.
8. Scheetz MH, Wunderink RG, Postelnick MJ et al. Potential impact of vancomycin pulmonary distribution on treatment outcomes in patients with methicillin-resistant Staphylococcus aureus pneumonia. Pharmacotherapy 2006;26:539-550.
9. Sakoulas G, Moise-Broder PA, Schentag J et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004;42: 2398-2402.
10. Moise-Broder PA, Sakoulas G, Eliopoulos GM et al. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 2004; 38:1700-1705.
11. Moise PA, Smyth DS, El-Fawal N et al. Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2008;61:85-90.
12. Hidayat LK, Hsu DI, Quist R et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: Efficacy and toxicity. Arch Intern Med 2006;166:2138-2144.
13. Liu C, Bayer A, Cosgrove SE et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children (2011). Clin Infect Dis 2011;52:e18-55.
14. Dryden M, Andrasevic AT, BassettiMet al. A European survey of antibiotic management of methicillinresistant Staphylococcus aureus infection: Current clinical opinion and practice (2010). Clin Microbiol Infect 2010;16(Suppl 1):3-30.
15. Fowler VG Jr., Boucher HW, Corey GR et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006;355:653-665.
16. Walkey AJ, O'donnell MR, Wiener RS. Linezolid vs glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: A meta-analysis of randomized controlled trials. Chest 2011;139:1148-1155.
17. Chemaly RF, Hachem RY, Husni RN et al. Characteristics and outcomes of methicillin-resistant Staphylococcus aureus surgical-site infections in patients with cancer:A case-control study. Ann Surg Oncol 2010;17:1499-1506.
18. Kang CI, Song JH, Ko KS et al. Clinical features and outcomes of Staphylococcus aureus infections in non-neutropenic cancer patients. Support Care Cancer 2012;20:483-488.
19. Espersen F, Frimodt-Moller N, Rosdahl VT et al. Staphylococcus aureus bacteremia in patients with hematological malignancies and/or agranulocytosis. Acta Med Scand 1987;222:465-470.
20. Gonzalez-Barca E, Carratala J, Mykietiuk A et al. Predisposing factors and outcome of Staphylococcus aureus bacteremia in neutropenic patients with cancer. Eur J Clin Microbiol Infect Dis 2001;20:117-119.
21. Skov R, Gottschau A, Skinhoj P et al. Staphylococcus aureus bacteremia: A 14-year nationwide study in hematological patients with malignant disease or agranulocytosis. Scand J Infect Dis 1995;27:563-568.
22. Cuervo SI, Cortes JA, Sanchez R et al. Risk factors for mortality caused by Staphylococcus aureus bacteremia in cancer patients. Enferm Infecc Microbiol Clin 2010;28:349-354.
23. Mermel LA, Allon MA, Bouza E et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the infectious diseases society of america. Clin Infect Dis 2009;49:1-45.
24. Kullar R, Davis SL, Levine DP et al. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: Support for consensus guidelines suggested targets. Clin Infect Dis 2011;52:975-981.
25. Lubin AS, Snydman DR, Ruthazer R et al. Predicting high vancomycin minimum inhibitory concentration in methicillin-resistant Staphylococcus aureus bloodstream infections. Clin Infect Dis 2011;52:997-1002.
26. Lodise TP, Graves J, Evans A et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008;52:3315-3320.
27. Musta AC, Riederer K, Shemes S et al. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: Trends over 11 years. J Clin Microbiol 2009;47: 1640-1644.
28. Soriano A, Marco F, Martinez JA et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008;46: 193-200.
29. Takesue Y, Nakajima K, Takahashi Y et al. Clinical characteristics of vancomycin minimum inhibitory concentration of 2 g/mL methicillin-resistant Staphylococcus aureus strains isolated from patients with bacteremia. J Infect Chemother 2010;17: 52-57.
30. Campo M, Hachem R, Jiang Y et al. Panton valentine leukocidin exotoxin has no effect on the outcome of cancer patients with methicillin-resistant Staphylococcus aureus (MRSA) infections. Medicine (Baltimore) 2011;90:312-318.
31. Holmes NE, Turnidge JD, Munckhof WJ et al. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis 2011;204:340-347.
32. Holland TL, Fowler VGJ. Vancomycin minimum inhibitory concentration and outcome in patients with Staphylococcus aureus bacteremia: Pearl or pellet? J Infect Dis 2011;204:329-331.
33. Gould IM, Cauda R, Esposito S et al. Management of serious methicillin-resistant Staphylococcus aureus infections: What are the limits? Int J Antimicrob Agents 2011;37:202-209.
34. Lefebvre M, Jacqueline C, Amador G et al. Efficacy of daptomycin combined with rifampicin for the treatment of experimental methicillin-resistant Staphylococcus aureus (MRSA) acute osteomyelitis. Int J Antimicrob Agents 2010;36:542-544.
35. Garrigos C, Murillo O, Euba G et al. Efficacy of usual and high doses of daptomycin in combination with rifampin versus alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother B 2010; 54:5251-5256.
36. Moschovi M, Trimis G, Tsotra M et al. Efficacy and safety of linezolid in immunocompromised children with cancer. Pediatr Int 2010;52:694-698.
37. Lewis T, Chaudhry R, Nightingale P et al. Methicillin-resistant Staphylococcus aureus bacteremia: Epidemiology, outcome, and laboratory characteristics in a tertiary referral center in the UK. Int J Infect Dis 2011; 15:e131-e135.
38. Arbeit RD, Maki D, Tally FP et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38:1673-1681.